Prognostic significance of AI-identified markers for isoniazid resistance in Mycobacterium tuberculosis

Author:

Valafar Siavash,Valafar Aram

Abstract

AbstractAntibiotic resistance in tuberculosis (TB), a disease that kills 1.5 million people annually, is a great concern. The emergence of drug resistance inM. tuberculosis, the obligate pathogen of TB seems to follow an order. In most cases resistance to isoniazid (INH) emerges first, followed by rifampicin, then either pyrazinamide or ethambutol, and finally followed by resistance to second-line drugs. Prevention of emergence of INH resistance can go a long way to prevent the emergence of resistance to other drugs. In this manuscript we present the prognostic value of specific mutations in the hope that resistance can be e predicted and hence avoided. Here we present evidence that resistance to INH follows a stepwise evolutionary trajectory in most cases. This information can therefore be used to predict and avoid INH resistance. In our approach, we used genomic and phenotypic data from over 16,000 samples collected by two large databases, the TB Portals and the CRyPTIC consortium. We used a deep learning neural network model to identify promising mutations using the TB Portal data. We then tested the prognostic value of the identified mutations using the CRyPTIC consortium data. In this manuscript, we estimate a prognostic accuracy of 73% for correctly predicting the emergence of three canonical INH resistance mutations (katG315, inhA-15, and inhA-8) by using two prognostic markers. Additional time course samples and analysis will undoubtedly uncover prognostic markers for other evolutionary trajectories that lead to resistance.

Publisher

Cold Spring Harbor Laboratory

Reference20 articles.

1. World Health Orgnaization. Global tuberculosis report 2023. 7 November 2023. 75 https://www.who.int/publications/i/item/9789240083851 (2023).

2. Treatment Strategy for Rifampin-Susceptible Tuberculosis

3. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

4. World Health Organization, (WHO). GLOBAL TUBERCULOSIS REPORT 2021.

5. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3